Reeve Stoffer Explains Why a Reset Might Have Been the Best Thing...

Why It Matters

Remote stroke intervention could save millions of brain cells, creating a high‑value market while reshaping emergency care delivery.

Key Takeaways

• Telesurgical stroke tech could cut treatment delays dramatically.
• Six companies compete to deliver remote thrombectomy solutions.
• XCAT achieved 100‑mile remote procedure successfully in Panama.
• Remedy Robotics testing neuro‑intervention across Canada with promising results.
• Industry uses race narrative to accelerate medtech innovation.

Summary

The Device Talks podcast spotlighted the emerging field of telesurgical stroke treatment, exploring how remote thrombectomy could dramatically shorten the critical "time‑is‑brain" window. Host Tom Slumby and guests examined a nascent competitive landscape, highlighting six innovators racing to bring remote neuro‑vascular procedures to market. Key insights included the absence of an FDA‑cleared U.S. product, the strategic use of the FDA’s TAP program, and the varied technical approaches—from XCAT’s proven 100‑mile remote thrombectomy in Panama to Nanoflex’s electromagnetic wire‑steering concept. Companies such as Remedy Robotics, Microbot Medical, and Cente showcased pilot studies in Canada and other international sites, underscoring a global push to validate safety and efficacy. Notable examples featured XCAT’s long‑distance procedure, Remedy Robotics’ cross‑country neuro‑intervention trial, and Cente’s haptic joystick that mimics tactile feedback for remote surgeons. The editorial team framed the sector as a race, prompting each firm to articulate why they could win, which added a sports‑like narrative to traditionally technical coverage. The race narrative could accelerate funding, regulatory engagement, and clinical adoption, potentially delivering life‑saving technology to stroke patients faster than traditional pathways. If successful, remote thrombectomy may reshape emergency care logistics, expand market opportunities for medtech firms, and set a precedent for other telesurgical applications.

Original Description

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi visits his MedTech happy place — renal denervation — with Recor Medical COO Helen Reeve Stoffer. Reeve Stoffer joined the company shortly before the bottom fell out of the renal denervation market in 2014. This interview picks up from that point and follows Recor's pursuit of FDA approval to where denervation technology may be applied next.

This week’s FOMO features a portion of a keynote interview with Manny Villafaña, MedTech legend and CEO of Medical 21. The conversation took place at DeviceTalks Minnesota and focuses on the dream that saved St. Jude Medical.

Skyler Rivera, associate editor of MassDevice, gives us a preview of her upcoming feature in Medical Design & Outsourcing magazine on the race to provide telesurgery capabilities to surgical robotic systems.

***

Enjoy the show? Follow [DeviceTalks Weekly](https://devicetalksweekly.castos.com/subscribe) on all major podcast players + Follow us on [YouTube.com/@DeviceTalks](https://www.youtube.com/@DeviceTalks) to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

00:02:42 Associate Editor Skyler Rivera's path the MedTech (and MassDevice)

00:06:00 MDO covers the race for robotic telesurgery platforms in stroke

00:11:12 Rivera reviews the race leaders

00:16:30 FOMO Studio - Manny Villafana, MedTech Legend and CEO of Medical 21

00:28:19 Keynote Interview - Helen Reeve Stoffer, COO, Recor Medical